The overall incidence of DDR pathway alterations in localized prostate cancer approaches 30%. To assess the potential pathologic significance of DDR pathway in localized prostate cancer, we analyzed the TCGA prostate cancer database for mutations or copy number alterations of the following twelve genes (CHEK1, CHEK2, RAD51, BRCA1, BRCA2, MLH1, MSH2, ATM, ATR, MDC1, PARP1, and FANCF). This evidence concerns the gene MDC1 and prostate cancer.